Please Share:: 
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
GLENMARK: Key takeaways
At least 18-20% growth in India likely in FY2012E.
While Glenmark has 7 NCEs (including Croflemer) in the pipeline, it will focus on
conducting trials on 4 NCEs—(1) 2 phase II trials for 4039, (2) phase I trial for GBR500,
(3) phase I for 117536 and (4) phase III for Croflemer.
Glenmark looking for a partner to out license Melogliptin. For now no further trials are
being conducted on Melogliptin.
While Glenmark got 9 approvals in 9MFY11, 3-4 products were launched in 9MFY11,
including Tarka.
14 OC filings have been made.
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
GLENMARK: Key takeaways
At least 18-20% growth in India likely in FY2012E.
While Glenmark has 7 NCEs (including Croflemer) in the pipeline, it will focus on
conducting trials on 4 NCEs—(1) 2 phase II trials for 4039, (2) phase I trial for GBR500,
(3) phase I for 117536 and (4) phase III for Croflemer.
Glenmark looking for a partner to out license Melogliptin. For now no further trials are
being conducted on Melogliptin.
While Glenmark got 9 approvals in 9MFY11, 3-4 products were launched in 9MFY11,
including Tarka.
14 OC filings have been made.
No comments:
Post a Comment